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The success of HIV/AIDS treatment depends on the ef-
fective and appropriate use of antiretroviral agents 
(ARVs). Resource-limited countries bear the brunt of 
this public health crisis, and their responses necessarily 
differ from those of industrialised nations. Ideally, ARV 
administration and patient monitoring in public pro-
grammes should be standardised, with free, effective, 
tolerable drugs and simple regimens to promote patient 
compliance. 
Most developing countries employ the World Health 
Organization (WHO) public health approach to antiret-
roviral treatment, which aims to maximise patient sur-
vival using highly active antiretroviral therapy (HAART) 
with a combination of three agents from different drug 
classes in order to enhance efficacy and minimise the 
development of resistance through the promotion of 
adherence.1 
Short-term Effectiveness and 
Safety of HAART in the form of a 
Generic Fixed-dose Combination 
of Stavudine, Lamivudine and 
Nevirapine (Triviro) in HIV-1-infected 
Adults in Zimbabwe 
CLINICAL
A G Duse1, A Morar2, I Landman3, W J H Vermaak4, H Schoeman5, M J Kruger6, E Janse van Rensburg4, R Lüthy7, S Singh8
1School of Pathology of the Witwatersrand, Department of Clinical Microbiology and Infectious Diseases, National Health Laboratory Service, South Africa 
2Colin Saunders Hospital, Triangle, Zimbabwe 
3Well Women’s Clinic, Harare, Zimbabwe 
4Tshwane Academic Division, NHLS, University of Pretoria, South Africa 
5Clinstat, Pretoria 
6Ranbaxy Medical Director: Europe, London, UK 
7Connaught Clinic, Swiss AIDS Care Foundation, Harare 
8Ranbaxy Medical Director: Africa, Centurion, South Africa
Corresponding author: H S Schoeman (clinstat@telkomsa.net)
Objectives. To assess the effectiveness and safety of a twice-daily regimen of a generic fixed-dose combination 
(FDC) of stavudine, lamivudine and nevirapine (Triviro) in a cohort of Zimbabwean HIV-1-positive adults.
Design. A prospective, open-label, one-arm study of antiretroviral-naïve adults with CD4 counts <200 cells/µl. 
Fifty-three intention-to-treat (ITT) patients were enrolled and monitored for 4 months.
Setting. Three primary health care facilities in Zimbabwe.
Outcome measures. Efficacy criteria included plasma HIV-1 RNA load, CD4 counts, patient weight and Karnofsky 
performance scores. Toxicity was assessed by clinical evaluation and laboratory tests. 
Results. There was a significant 3.0 log10 decrease in viral load at weeks 8 and 16 for both groups. Viral loads ≤400 
copies/ml were achieved in 96% of per protocol (PP) and 85% of ITT patients at 8 and 16 weeks. At 4 months 
85% of the PP group and 76% of the ITT group achieved undetectable viral loads. There was a significant increase 
in median CD4 counts of 101 cells/µl for PP and 86 cells/µl for the ITT analysis. The number of PP patients with 
Karnofsky scores of 100 improved from 10 (21%) to 38 (81%) and BMI increased by an average of 1.15 kg/m2. Of 
the 134 adverse events recorded, 4 (3%) were severe. Of 16 adverse drug reactions in 10 patients, 13 were ascribed 
to nevirapine. One adverse reaction resulted in withdrawal from the study. 
Conclusion. The effectiveness and safety of Triviro was comparable to that seen with other formulations, and our 
results support the use of this FDC in Zimbabwe and elsewhere.
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Adherence to treatment programmes is of particular im-
portance to prevent treatment failure and development 
of drug resistance, since patient monitoring and avail-
ability of alternative drugs is often limited in resource-
limited countries. Patient compliance in these countries 
has been found to be at least as good as that in de-
veloped regions,2 but obstacles to long-term adherence 
include medication cost and affordability in the health 
care setting, access to treatment, side-effects and the 
complexities of treatment schedules. 
Companies producing generic drugs were the first to 
market fixed-dose combination (FDC) ARV preparations, 
and these drugs have won broad acceptance in the de-
veloping world. A study by Chien in 2007 showed that 
the vast majority of first-line ARV drugs in sub-Saharan 
Africa are supplied by generic companies.3 This is in large 
part due to the fact that the average price of generic 
drugs is usually a fraction of that of brand-name equiv-
alents. FDCs comprise a third of the drugs purchased 
in the region, with the stavudine/lamivudine/nevirap-
ine (d4T/3TC/NVP) combination constituting the larg-
est proportion at 20%. FDCs form an important pillar in 
promoting adherence, since they greatly reduce pill bur-
den, dosing frequency and prescription errors. As with 
brand-name drugs, generic formulations are subject to 
stringent quality control standards. However, in order to 
ensure patient safety and public support, it is essential 
to ensure that counterfeit generic or brand name drugs 
do not find their way onto the market. 
The Triviro (d4T/3TC/NVP) (Ranbaxy Laboratories, Centu-
rion, South Africa) combination HAART is similar in for-
mulation to Triomune (Cipla, Mumbai, India) and GPO-
VIR (Thai Government Pharmaceutical Organisation). 
It has been shown to be comparable both in terms of 
bioequivalence4 and safety5 to each of its components.
While several studies have been conducted in Central 
and West Africa using d4T/3TC/NVP,6,7 few have reported 
the use of this FDC in the southern African region. Zim-
babwe has one of the highest HIV prevalence rates in 
southern Africa, which in 2005 was estimated at 33% in 
adults aged 15 - 49.8  
This study was designed to evaluate the short-term ef-
fectiveness and safety of Triviro in an eligible cohort of 
HIV-1-positive patients in Zimbabwe. The goals were to 
assess virological, immunological and clinical improve-
ment, tolerability and safety profile in treatment-naïve 
participants.
This prospective, open-label, one-arm observational 
study was conducted at three primary health care facili-
ties in Zimbabwe (Zimbabwean Swiss AIDS Care Founda-
tion, the Colin Saunders Hospital and the Well Women’s 
Clinic). Enrolment took place from May 2005 until Feb-
ruary 2006. 
The enrolment criteria for patients who qualified were: 
>18 years of age, HIV-1 positive at WHO stage I, II or III 
with CD4 counts <200 cells/µl or advanced WHO stage 
III disease presenting with recurrent or persistent oral 
thrush and/or recurrent invasive bacterial infections ir-
respective of CD4 count. Exclusion criteria were inability 
to provide informed consent, a history of hypersensitiv-
ity to treatment components, alcohol or drug abuse, ac-
tive pulmonary tuberculosis, acute/active opportunistic 
infections, a history of previous ARV therapy, pregnancy 
or breastfeeding, female patients not using contracep-
tion, evidence of peripheral neuropathy, haemoglobin 
concentration <9.0 g/dl, platelet count <75 000×109/l, 
aspartate aminotransferase (AST) or alanine aminotrans-
ferase (ALT) ≥3 times the upper limit of normal (ULN), 
serum creatinine ≥1.6 times the ULN, serum amylase 
≥1.6 times the ULN, total bilirubin ≥30 µmol/l, and mal-
absorption or severe chronic persistent diarrhoea. 
Informed consent was obtained from all participants. 
The Medicines Control Authority of Zimbabwe approved 
the protocol and provided a provisional licence for the 
use of Triviro before the study was conducted.
Two fixed-dose tablet formulations were considered for 
use as study medication: Triviro-30 (150 mg 3TC, 30 mg 
d4T and 200 mg NVP) for patients with a body weight 
<60 kg and Triviro-40 (150 mg 3TC, 40 mg d4T and 200 
mg NVP) for patients with a body weight >60 kg. This 
study was performed before revision of the WHO guide-
lines on stavudine dosing, where 30 mg stavudine is the 
recommended dose regardless of body weight.9
A 2-week nevirapine lead-in dose was used to assess tol-
erability of the formulation, especially nevirapine, and to 
decrease the risk of adverse reactions. During this pe-
riod patients were provided with a single tablet of Tri-
viro-30 or Triviro-40 for administration in the morning 
and a single tablet of Coviro LS 30 or 40, a stavudine/
lamivudine nucleoside combination, in the evening that 
corresponded with the dose of stavudine in the Triviro 
formulation. Patients who experienced no significant 
drug-related adverse events were advanced to therapy 
with Triviro-30 or Triviro-40 twice daily after the initial 
2-week treatment period.
Patients were excluded from the study if they were lost to 
follow-up (failure to visit clinic within a week of sched-
uled follow-up visit), or experienced serious intolerable 
adverse events or clinical deterioration indicative of viral 
resistance. Treatment of other ailments was continued 
unless contraindicated for concomitant use in combina-
tion with the study medication. 
Methods
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Patient monitoring was performed within 2 weeks of 
treatment initiation to establish drug tolerability. There-
after follow-up assessments at 4 weeks, 8 weeks and 4 
months were performed. CD4 counts were measured at 
baseline and 4 months. HIV-1 RNA viral load testing was 
performed at baseline, 8 weeks and 4 months. Karnofsky 
scoring was assessed at baseline and 4 months. Potential 
toxicity of the study medication was assessed by clinical 
examination and monitoring of levels of haemoglobin, 
white blood cells and platelets assessed at the screening 
visit, week 8 and month 4. Serum transaminases were 
measured at the screening visit, 2, 4 and 8 weeks and 4 
months. Serum creatinine and amylase were measured 
at screening, week 2 and month 4. The Aids Clinical Trials 
Group (ACTG) rating was used to assess toxicity.10
LAborAtory AssAys
All HIV viral load and CD4 measurements were 
performed by the laboratory of Vermaak and Partners, 
Pretoria, South Africa. The Nuclisens EasyQ HIV-1 assay 
(bioMerieux, Marcy l’Etiole, France) was used for viral 
load measurements.  
stAtIstICs
Viral loads and CD4 cell counts were summarised us-
ing descriptive statistics. Changes in the medians of viral 
loads (using log10 transformation) and CD4 cell counts 
relative to baseline were tested for significance using the 
Wilcoxon signed rank test. Proportions of subjects with 
plasma HIV-1 RNA levels ≤25, <50 and <400 copies/ml 
were assessed using the binomial (exact) 95% confi-
dence interval. Changes in blood pressure, body mass 
index (BMI), pulse rate, respiratory rate, temperature and 
haemoglobin were analysed using Student’s paired t-
test. Changes in median serum aspartate transaminase, 
alanine transaminase, bilirubin, serum creatinine, serum 
amylase, white cell counts, platelet counts and Karnofsy 
score were tested for significance using the Wilcoxon 
signed rank test. The proportion of patients who had a 
Karnofsky score of 100 at baseline and at month 4 was 
also summarised. Missing data were replaced with the 
last available observation for CD4 cell count and viral 
load data. Statistical analysis was performed using PC 
SAS 8.2 (SAS Institute Inc., Cary, NC) at 5% two-sided 
alpha levels. 
Out of 55 patients screened, 53 were enrolled at three 
participating primary health care clinics in Zimbabwe. 
Of this intention-to-treat (ITT) group ( i.e. patients who 
received at least 1 dose of drug), 6 patients withdrew or 
were excluded from the study due to: adverse events (2), 
non-compliance (2), loss to follow up (1) and failure to 
attend the clinic (1). One of the 2 patients who withdrew 
as a consequence of reported adverse events presented 
with immune reconstitution syndrome (tuberculosis) 
and died 2 weeks after withdrawal from the study, and 
the other presented with a severe rash thought to be 
caused by nevirapine. The demographics of the ITT group 
are shown in Table I. 
VIrAL ANd IMMuNoLogICAL respoNse
There was a significant decrease in HIV-1 RNA levels 
from the median (interquartile range (IQR)) at baseline 
of 4.4 log10 copies/ml to 1.4 log10 copies/ml (3.0 log10 de-
crease) at week 8, which was maintained at month 4, 
for both ITT and PP (i.e. patients who followed the study 
protocol strictly) groups (p<0.0001) (Table II). The pro-
portion of patients with viral loads of ≤400 copies/ml 
was 96% in the PP group and 85% in the ITT group at 
both 8 and 16 weeks of treatment. These results are pre-
sented in Table III and Fig. 1. At 4 months, 87.2% of the 
PP group had viral RNA levels ≤50 copies/ml, with 85.1% 
achieving undetectable levels (≤25 copies/ml). Of the ITT 
group, 77.4% had viral loads ≤50 copies/ml and 75.5% 
≤25 copies/ml (Table III).  
resuLts
	 																Baseline		 																		Week	8		 															Month	4	
Statistic	 ITT	 PP	 ITT	 PP	 ITT	 PP	
N 53 47 53 46* 53 47
Median 4.431 4.3979 1.398 1.3979 1.398 1.3979
IQR (Q1 - Q3) 4.2041 - 4.9085 4.1139 - 4.8195 1.3979 - 1.9638 1.3979 - 1.6435 1.3979 - 1.3979 1.3979 - 1.3979
*Data for 1 subject not available.
tAbLe II. VIrAL LoAd, Log10 (hIV rNA CopIes/ml) For Itt ANd pp popuLAtIoNs At bAseLINe,  
WeeK 8 ANd MoNth 4
Variable	 	 Statistics
Age	(yrs)  
N  53
Mean±SD  41.6±7.63
Min, max  28.6, 56.4
Sex	(N	(%))	 	 	
Female  27 (50.9%)
Male  26 (49.1%)
Race	(N	(%))
Black   48 (90.6%)
Caucasian  2 (3.8%)
Mixed race  3 (5.7%)
Viral	load   2 700
CD4   117
tAbLe I. deMogrAphIC ChArACterIstICs  
oF the Itt group At bAseLINe
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A significant improvement in the CD4 cell counts from 
baseline to month 4 was observed, with an increase in 
the median count of 86 cells/µl for the ITT group and 101 
cells/µl for the PP group (Fig. 2). 
physIoLogICAL pArAMeters
Participant body weight increased significantly after 
4 months of treatment in the PP group, with a mean 
increase in weight of 3.22 kg, corresponding to a BMI 
increase of 1.15 kg/m2. Respiratory rate decreased sig-
nificantly from baseline (an average decrease of 1.3 
breaths/min), while blood pressure, pulse rate and tem-
perature remained essentially unchanged. The Karnofsky 
performance score at 100 was found to markedly im-
prove in the PP group from 10 patients (21.3%) at base-
line to 38 (80.9%) at the conclusion of the study. 
toLerAbILIty 
Laboratory analyses of markers to potentially indicate 
toxicity was performed. AST levels were shown to de-
crease 2 weeks after initiation of treatment, but ap-
proached baseline levels at later visits. ALT levels were 
elevated at month 4, and serum creatinine was increased 
at week 2. Amylase was shown to decrease at month 
4, while significant declines in bilirubin were seen at all 
time points. While the median and IQR values for all the 
enzymatic parameters did not exceed grade 1 according 
to the ACTG guidelines,10 there were instances where the 
maximum values were indicative of grade 2 or 3. A single 
patient had AST and ALT levels in the grade 2 (2.6 - 5.0 
times ULN) range at screening, which decreased to be-
low threshold during treatment. Another patient showed 
elevated levels of AST and ALT (grade 3; 5.1 - 10 times 
ULN) at week 8, which fell to normal at week 16. Serum 
creatinine levels were within the grade 1 (1.1 - 1.3 times 
ULN) range, except for 1 patient at grade 2 (1.4 - 1.8 
times ULN) at 2 weeks, which normalised by 16 weeks. 
Analysis of amylase levels showed 4 patients at grade 2 
(1.1 - 1.5 times ULN) and grade 3 (1.6 - 2.0 times ULN), 
respectively. This changed to 5 patients at grade 2 and 
1 at grade 3 at 16 weeks. One patient had a grade 3 (2.6 
- 5.0 times ULN) bilirubin level at week 4, which nor-
malised by week 16. Although slightly elevated levels of 
haemoglobin and platelets were noted at 4 months, no 
changes were seen in the lymphocyte counts. 
AdVerse eVeNts ANd drug reACtIoNs
One hundred and thirty-four adverse events were re-
corded, the commonest being headache in 6 patients 
(11.3%), diarrhoea in 5 (9.4%), cough in 4 (7.5%), and 
loss of appetite and vomiting in 3 (5.7%). The majority 
(74.6%) of these events were judged to be mild, with 
22.4% moderate and 3% severe. Eighty-one per cent 
of these events were considered to be unrelated to the 
study medication, 3.7% to have a remote possibility of 
causal relatedness, 11.9% a possible connection and 3% 
a probable connection. More than 1 adverse event was 
noted in 40 patients (76%). Sixteen adverse drug reac-
tions were noted in 10 patients, of which 13 were as-
cribed to nevirapine (81.3%) and 3 (18.8%) to stavudine. 
The majority (56.3%) of these reactions were mild, 37.5% 
were moderate, and there was one instance (6.3%) of a 
severe rash that resulted in withdrawal from the study. 
In this observational study of Triviro usage in Zimbabwe, 
we found effective viral suppression and immunologi-
cal recovery at month 4 after initiation of generic FDC 
HAART in the majority of the participants. A significant 
virological improvement after 4 months was noted, with 
a 3.0 log10 decline in the median HIV-1 RNA levels from 
Fig. 1. Viral loads in the ITT and PP groups at week 8 and  
month 4.
Fig. 2. CD4 counts for ITT and PP populations at baseline and 
month 4.
dIsCussIoN
	 																														Week	8	 																													Month	4
	 ITT	 PP	 ITT	 PP
≤25 copies/ml  95% CI  31 (58.5%) 44.1 - 71.9% 31 (67.4%) 52.0 - 80.5% 40 (75.5%) 61.7 - 6.2 40 (85.1%) 71.7 - 93.8%
p-value† 0.2164    0.0183* 0.0002** <0.0001** 
≤50 copies/ml  95% CI  35 (66.0%) 51.7 - 78.5% 35 (76.1%) 61.2 - 7.4% 41 (77.4%) 63.8 - 87.7% 41 (87.2%) 74.3 - 95.2% 
p-value† 0.0195* 0.0004** <0.0001** <0.0001** 
≤400 copies/ml  95% CI  45 (84.9%) 72.4 - 93.3% 44 (95.7%) 85.2 - 99.5% 45 (84.9%) 72.4 - 93.3% 45 (95.7%) 85.5 - 99.5% 
p-value†  <0.0001** <0.0001** <0.0001** <0.0001**
*Significant at 5% level, **Significant at 1% level.
†Two-sided binomial test (H0: proportion = 0.5).
tAbLe III. NuMber (%) oF Itt ANd pp pAtIeNts WIth VIrAL LoAds ≤25, ≤50 ANd ≤400 CopIes/ml At  
WeeK 8 ANd MoNth 4
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baseline. Similarly, a significant immunological improve-
ment was seen, with an average increase of 101 CD4 
cells/µl for the PP-treated group. These results compare 
favourably with, and in some cases exceed, the endpoints 
of similar studies.6,7 Patient well-being was also found to 
be enhanced, with a marked increase in BMI and in the 
number of patients with a Karnofsky score of 100 by the 
end of 4 months. The majority of adverse events were 
not judged to be severe, although there was one with-
drawal due to debilitating rash. The adverse drug reac-
tions observed were also typical for the drugs used, and 
are mentioned in the product information.
The d4T/3TC/NVP FDC used in this study has previously 
been used as HAART therapy for advanced AIDS care11 
and is increasingly being used for paediatric treatment, 
with oral formulations facilitating easier dosage and in-
creased compliance.12 Although adult trials have been 
performed using d4T/3TC/NVP formulations in other re-
gions, few studies have been performed in southern Afri-
ca. The reports to date are on the use of the combination 
for the treatment of AIDS-associated Kaposi’s sarcoma 
in KwaZulu-Natal, South Africa13 and for prevention of 
vertical transmission of HIV-1 in Mozambique,14 and an 
initial report of its use in adults in South Africa.15 
The present study has some limitations. A longer-term 
study is needed to establish toxicity in patients us-
ing what could be lifelong treatment, especially given 
reports from Thailand of metabolic complications such 
as dyslipidaemia.16 Testing for resistance was not per-
formed in our study, but will become critical in light of 
cross-resistance that has been described in second-line 
treatment-naïve patients failing the d4T/3TC/NVP treat-
ment.17 
The positive longer-term experiences of other sites with 
Triomune18,19 and Triviro20 suggest that use of these ge-
neric HAART FDCs in southern Africa could be consid-
ered as first-line therapy.  
In conclusion, our short-term results support the use of 
Triviro, and d4T/3TC/NVP FDCs in general, to treat HIV-1 
positive adults. 
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